title: P-TEFb as a target to reactivate latent HIV: two Brds are now in hand.
abstract: Comment on: Boehm D, et al. Cell Cycle 2013; 12(3): In this issue.
authors: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. arice@bcm.edu
authors: Andrew P
authors: AP
authors: Rice
mesh_terms: D018797:Cell Cycle Proteins; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*; D000092468:Bromodomain Containing Proteins
chemical_list: D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D017346:Protein Serine-Threonine Kinases; D014157:Transcription Factors; D054322:tat Gene Products, Human Immunodeficiency Virus; C098415:BRD2 protein, human; D000092468:Bromodomain Containing Proteins; C441289:BRD4 protein, human
keywords: Brd2; Brd4; CDK9; HIV latency: HIV Tat; JQ1; P-TEFb